Stoke Therapeutics share price logo

Stoke Therapeutics

NASDAQ: STOK

Mid Cap

$32.16

+0.89

(+2.85%)

as on

Stoke Therapeutics Stock Performance

as on August 18, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $31.16
    $32.52
    downward going graph

    3.11%

    Downside

    1.12%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $17.95
    $40.22
    downward going graph

    44.19%

    Downside

    25.06%

    Upside

    downward going graph

Stoke Therapeutics share price movements today

Previous Close
$31.27
Open
$31.20
Volume
400.8K
Market Cap
$2.0B
Day's Low - High
$31.16 - $32.52
52 Week Low - High
$17.95 - $40.22

Stoke Therapeutics Historical Returns

1 Month Return
+ 7.64 %
3 Month Return
+ 3.96 %
1 Year Return
+ 71.72 %
3 Year Return
+ 462.41 %
5 Year Return
+ 20.18 %

Stoke Therapeutics Stock Fundamentals & Key Indicators

Check Stoke Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.0B

EPS (TTM)

-3.36

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-9.32

Industry PE ratio

-13.046547619047619

PEG Ratio

-0.06689430161861812

EBITDA

-205.4M

Revenue (TTM)

27.6M

Profit Margin

84.67%

Return On Equity TTM

-59.36%

Stoke Therapeutics Stock Valuation

Track how Stoke Therapeutics P/E has moved over time to understand its valuation trends.

Stoke Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-264.50x)

December 31, 2025

Today (-264.50x)

December 31, 2025

Industry (-13.05x)

December 31, 2025

Highest (-2.21x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -264.50x

Stoke Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Stoke Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Stoke Therapeutics image
Stoke Therapeutics
BUY$2.0B20.18%-9.3284.67%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Stoke Therapeutics Stock including INR - Dollar returns

The Stoke Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Stoke Therapeutics investment value today

Current value as on today

₹1,93,356

Returns

₹93,356

(+93.36%)

Returns from Stoke Therapeutics Stock

₹76,606 (+76.61%)

Dollar Impact

₹16,750 (+16.75%)

Analyst Recommendation on Stoke Therapeutics Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Stoke Therapeutics. Average target price of $47

Stoke Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Stoke Therapeutics.

What analysts predicted

31.57%UPSIDE

Target Price

$47

Current Price

$32.16

Analyzed by

10 Analysts

Target

$47.00

Stoke Therapeutics target price $47, a slight upside of 31.57% compared to current price of $32.16. According to 10 analysts rating.

Indian Investors' Interest in Stoke Therapeutics Stock

Search interest for Stoke Therapeutics Stock has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:22% versus previous 30 day period

Stoke Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
4
4
4
22
158
13
10
1
6
9
Gross Profit
3
3
4
22
158
13
9
0
5
8
Operating Income
-28
-29
-30
-13
111
-27
-43
-61
-53
-65
EBITDA
-25
-25
-25
-9
114
-23
-38
-56
-45
-64
Interest Expense
-
-
-
-
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
1
1
1
Income Before Tax
-26
-25
-26
-10
114
-23
-39
-57
-50
-61
Income Tax Expense
-
-
-
-
1
-
-1
-
-
-
Net Income
-26
-25
-26
-10
112
-23
-38
-57
-50
-61
Net Profit Margin
73.60%
77.02%
100.00%
100.00%
100.00%
100.00%
90.70%
24.75%
83.19%
87.80%

Stoke Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
12
8
36
184
Gross Profit
0
0
0
-1
-
12
8
36
184
Operating Income
-5
-12
-35
-53
-86
-104
-114
-101
-20
EBITDA
-5
-12
-31
-50
-84
-99
-102
-86
-5
Interest Expense
-
-
-
-
-
-
-
-
0
Depreciation
0
0
0
1
0
1
2
2
1
Income Before Tax
-5
-12
-32
-52
-85
-101
-104
-88
-6
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-5
-12
-32
-52
-85
-101
-104
-88
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%

Stoke Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
-25
-26
-10
112
-23
-38
-57
-50
-61
Operating Cash Flow
-24
-17
-21
-23
131
-25
-30
-30
-60
-56
Investing Cash Flow
9
-88
-30
0
13
-148
9
-61
50
9
Financing Cash Flow
1
120
8
0
1
0
3
92
84
1
Change in Cash
-12
14
-43
-21
146
-173
-18
0
74
-45

Stoke Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-5
-12
-32
-52
-85
-101
-104
-88
-6
Operating Cash Flow
-5
-10
-31
-42
-66
-31
-81
-86
45
Investing Cash Flow
0
0
-1
-1
-76
-45
105
-107
-186
Financing Cash Flow
5
115
149
108
1
46
53
131
97
Change in Cash
0
103
117
64
-142
-31
77
-63
-43

Mutual Funds that own Stoke Therapeutics Stock

Check out the Mutual Funds with significant holdings in Stoke Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.55956%
2296851
VANGUARD SPECIALIZED FUNDS
2.560961%
1652492
Fidelity Select Portfolios
2.390645%
1542594
Fidelity Securities Fund
1.70768%
1101902
Fidelity Concord Street Trust
1.017241%
656388
See all

Global Institutional Holdings in Stoke Therapeutics

Funds
Holdings
Felix Baker
5.17%
Vanguard
4.77%
iShares
4.14%
James E. Flynn
2.83%
SPDR
2.78%
See all

Stoke Therapeutics News & Key Events

  • img

    Today's Timeline - 13 July

    Mon, 05:00 PM

    -

    Stoke Therapeutics appoints Thomas McCauley, Ph.D., as Chief Scientific Officer to lead scientific strategy and advance its RNA medicines pipeline.

    Mon, 05:48 PM

    -

    Goldman Sachs initiates coverage of Stoke Therapeutics with a Buy rating and a $44 price target, citing blockbuster potential.

Insights on Stoke Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, STOK stock has moved up by 462.4%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 1.40M → 9.32M (in $), with an average increase of 55.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 460.9% return, outperforming this stock by 389.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 595.5% return, outperforming this stock by 133.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -50.00M → -61.61M (in $), with an average decrease of 23.2% per quarter

About Stoke Therapeutics

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
OrganisationStoke Therapeutics
Headquarters45 Wiggins Avenue, Bedford, MA, United States, 01730
IndustryBiotechnology
CEOMr. Ian F. Smith A.C.A., C.P.A.
E-voting on sharesClick here to vote

Key Management of Stoke Therapeutics

Name

Title

Mr. Jason Hoitt

Chief Patient Officer

Ms. Isabel Aznarez Ph.D.

Co-Founder & CTO

Mr. Jonathan Allan J.D.

Corporate Secretary, Compliance Officer & General Counsel

Susan Willson

Vice President of Corporate Communications

Mr. Ian F. Smith A.C.A., C.P.A.

CEO & Director

Dr. Adrian R. Krainer Ph.D.

Co-Founder & Independent Director

Mr. Thomas Edward Leggett

Chief Financial Officer

Dr. Edward M. Kaye M.D., Ph.D.

Advisor & Director

Dr. Thomas McCauley Ph.D.

Chief Scientific Officer

Ms. Sara Den Besten

Chief People Officer

FAQs

What is Stoke Therapeutics share price today?

Stoke Therapeutics share price today is $32.16 as on at the close of the market. Stoke Therapeutics share today touched a day high of $32.52 and a low of $31.16.

What is the 52 week high and 52 week low for Stoke Therapeutics share?

Stoke Therapeutics share touched a 52 week high of $40.22 on and a 52 week low of $17.95 on . Stoke Therapeutics stock price today i.e. is closed at $32.16,which is 20.04% down from its 52 week high and 79.16% up from its 52 week low.

What is Stoke Therapeutics's market capitalisation today?

Stoke Therapeutics market capitalisation is $0.00T as on .

How to invest in Stoke Therapeutics Stock (STOK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Stoke Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Stoke Therapeutics Shares that will get you 0.0466 shares as per Stoke Therapeutics share price of $32.16 per share as on August 18, 2026 at 1:29 am IST.

What is the minimum amount required to buy Stoke Therapeutics Stock (STOK) from India?

Indian investors can start investing in Stoke Therapeutics (STOK) shares with as little as ₹95.592 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.92 in Stoke Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Stoke Therapeutics share’s latest price of $32.16 as on August 18, 2026 at 1:29 am IST, you will get 0.3109 shares of Stoke Therapeutics. Learn more about fractional shares .

What are the returns that Stoke Therapeutics has given to Indian investors in the last 5 years?

Stoke Therapeutics stock has given 20.18% share price returns and 28.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?